639P - The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Anti-Cancer Agents & Biologic Therapy
Gastric Cancer
Presenter Hideaki Bando
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors H. Bando1, T. Doi2, K. Muro3, H. Yasui4, T. Nishina5, K. Yamaguchi6, S. Takahashi7, H. Hasegawa8, S. Nomura8, H. Kuno9, K. Shitara1, A. Sato8, A. Ohtsu1
  • 1Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 3Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-0021 - Nagoya/JP
  • 4Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 5Department Of Gastrointestinal Medical Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 6Department Of Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 7Department Of Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 8Office Of Clinical Research Support, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 9Department Of Diagnostic Radiology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP

Abstract

Background

American phase I studies have reported that the recommended dose of TAS-102 (trifluridine/tipiracil) was 25 mg/m2 b.i.d., although this schedule did not provide clinically relevant improvements in a phase II study of advanced gastric cancer (AGC). However, a pivotal phase III study revealed that TAS-102 at 35 mg/m2 b.i.d. provided a clinically relevant improvement in overall survival among patients with metastatic colorectal cancer. Thus, we re-evaluated the efficacy, safety, and pharmacokinetic (PK) parameters of TAS-102 at 35 mg/m2 b.i.d. in patients with AGC. In an expanded cohort, we also evaluated the safety and PK parameters of a 40 mg/m2 b.i.d. schedule.

Methods

All patients had undergone one or two previous chemotherapy regimens that contained fluoropyrimidine, platinum agents, and taxanes or irinotecan. In this study, we assessed the investigator-determined and the independent central review's disease control rate (DCR), response rate, progression-free survival (PFS), overall survival (OS), safety profiles, and PK profiles.

Results

Twenty-nine patients were assessable after completing the 35 mg/m2 b.i.d. schedule. The investigator-determined DCR was 65.5% (95% confidence interval [CI], 45.7–82.1%) and the independent central review's DCR was 51.9% (n = 27, 95% CI, 31.9–71.3%). The median PFS and OS were 2.9 months (95% CI, 1.1–5.3 months) and 8.7 months (95% CI, 5.7–14.9 months), respectively. The grade 3/4 adverse events included neutropenia (69.0%), leukopenia (41.4%), anemia (20.7%), and anorexia (10.3%). No AGC-specific toxicities were detected. In the expanded cohort, the averages of PK parameters dose-dependently increased for 6 patients treated with the 40 mg/m2 b.i.d. dosage. Although slightly higher grade 3–4 neutropenia (83.3%) and leukopenia (66.7%) were observed, the investigator-determined DCR was 50.0% (SD: 3; PD: 3) and no partial response cases were observed.

Conclusions

The 35 mg/m2 b.i.d. dose of TAS-102 provided positive efficacy and an acceptable toxicity profile in patients with AGC. A randomized, double-blind, placebo-controlled, phase III study is ongoing to validate these findings.

Clinical trial identification

UMIN000007421

Legal entity responsible for the study

Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Funding

The Renovation Project of Early and Exploratory Clinical Trial Center, National Cancer Center Research and Development Fund (24-A-1)

Disclosure

K. Muro, T. Nishina, A. Ohtsu: Honoraria: Taiho Pharmaceutical Company. S. Takahashi: Research funding: Taiho Pharmaceutical Company. S. Nomura: Japan Breast Cancer Research Group (JBCRG). Grants: Japan Agency for Medical Research and Development (AMED). A. Sato: Corporate-sponsored Research: Taiho, Boehringer-Ingelheim, Novartis, Bayer. All other authors have declared no conflicts of interest.